SchizophreniaPhase 3NCT07105098
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
A Phase 3 study testing NBI-1117568 in people with Schizophrenia, run by Neurocrine Biosciences at 20 sites in 5 countries.
Trial summary
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Schizophrenia
- What is being tested?
- NBI-1117568
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 284 participants
- Where
- 20 sitesin 5 countries
- Study dates
- 11 Aug 2025to Nov 2027
- Phase
- Phase 3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participant has a primary diagnosis of schizophrenia
- Participant is experiencing an acute exacerbation or relapse of symptoms and currently warrants hospitalization.
- Participants taking prohibited medications, including antipsychotics, must discontinue before study participation
- Participant is willing and able to remain in an inpatient setting for the study duration, follow instructions, and comply with the protocol requirements
Who cannot join
- Participant has known hypersensitivity to any component of the formulation of NBI-1117568
- Participant has an unstable or poorly controlled medical condition or chronic disease
- Participant is considered by the investigator to be at imminent risk of suicide or injury to self or others
- Participant has a diagnosis of moderate or severe substance use disorder (with the exception of nicotine or caffeine dependence) within 6 months prior to screening
- Participant has a positive alcohol test or drug screen for disallowed substances
- Participant has a history of poor or suspected poor compliance in clinical research studies and/or in the investigator's opinion, the participant is not capable of adhering to the protocol requirements.
- Note: Other protocol-specified inclusion/exclusion criteria may apply.
Trial locations and contacts
20 sites in 5 countries. Contact the study team or a site near you to ask about taking part.
20 sites in 5 countries
United States7 sites, 6 recruiting
- Completed
Neurocrine Clinical Site
Atlanta, Georgia, 30328
- Recruiting
Neurocrine Clinical Site
Culver City, California, 90230
- Recruiting
Neurocrine Clinical Site
Garden Grove, California, 92845
- Recruiting
Neurocrine Clinical Site
Hollywood, Florida, 33024
- Recruiting
Neurocrine Clinical Site
Little Rock, Arkansas, 72211
- Recruiting
Neurocrine Clinical Site
North Canton, Ohio, 44720
- Recruiting
Neurocrine Clinical Site
Riverside, California, 92506
Bulgaria4 sites, 3 recruiting
- Recruiting
Neurocrine Clinical Site
Pleven, 5802
- Recruiting
Neurocrine Clinical Site
Sliven, 8800
- Withdrawn
Neurocrine Clinical Site
Veliko Tarnovo, 5047
- Recruiting
Neurocrine Clinical Site
Vratsa, 3001
Hungary3 sites, 2 recruiting
- Recruiting
Neurocrine Clinical Site
Budapest, 1083
- Recruiting
Neurocrine Clinical Site
Gyöngyös, 3200
- Completed
Neurocrine Clinical Site
Győr, 9024
Romania3 sites, 2 recruiting
- Recruiting
Neurocrine Clinical Site
Brasov, 500123
- Recruiting
Neurocrine Clinical Site
Brasov, 507190
- Completed
Neurocrine Clinical Site
Bucharest, 41914
Serbia3 sites, 2 recruiting
- Withdrawn
Neurocrine Clinical Site
Belgrade, 11000
- Recruiting
Neurocrine Clinical Site
Gornja Toponica, 18202
- Recruiting
Neurocrine Clinical Site
Kragujevac, 34000
About this study
Official title: A Global, Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
- Conditions
- Schizophrenia
- Being tested
- NBI-1117568, Placebo
- Medical subject headings
- Schizophrenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NBI-1117568Drug
NBI-1117568 will be administered per schedule specified in the arm description.
PlaceboDrug
Placebo will be administered per schedule specified in the arm description.
| Study group | Role | What they receive |
|---|---|---|
| NBI-1117568 | Experimental | Participants will receive NBI-1117568 once daily (QD) orally from Day 1 to Day 35 for a total of 5 weeks. Receives: Drug: NBI-1117568 |
| Placebo | Placebo comparator | Participants will receive matching placebo QD orally from Day 1 to Day 35 for a total of 5 weeks. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5
Measured: Baseline, Week 5
Secondary outcomes (1)
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 5
Measured: Baseline, Week 5
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2025
- Study start11 Aug 2025
- Primary completionNov 2027 (estimated)
- Study completionNov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- More trials run by Neurocrine BiosciencesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 284 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Neurocrine Biosciences
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Development Lead, Study director, Neurocrine Biosciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07105098
- Sponsor's protocol ID
- NBI-1117568-SCZ3030
- Other IDs
- 2025-521215-39-00, 2025
- Status last verified
- Sep 2026
- First submitted
- 29 Jul 2025
- Last updated
- 25 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No